Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Clinical rationing

    Cash cravings Clinical rationing The total raised by private and public European biotechs increased by 57% to $9 billion in 2014 from $5.8 billion in 2013. Funding for companies in the clinic or with a marketed …

    Published on 5/25/2015
  • Figure: Europe's total demand

    Cash cravings Europe's total demand BioCentury projects that private and public European biotech companies with compounds in the clinic and beyond will need a record $6 billion to keep their programs on track …

    Published on 5/25/2015
  • Figure: Private demand

    Cash cravings Private demand The aggregate three-year demand for private European biotechs in the clinic and beyond is estimated to be $5 billion, slightly below the $5.1 billion in last year’s survey. On a euro …

    Published on 5/25/2015
  • Figure: Public demand

    Cash cravings Public demand The aggregate three-year capital demand for unprofitable European public biotechs in the clinic and beyond reached $946.6 million, up 62% from $585.8 million in the 2014 survey. …

    Published on 5/25/2015
  • Table: New funds

    Cash cravings New funds Since the start of 2014, at least 30 life science funds with a European presence are raising or have raised a total of more than $9 billion. (A) Invests in private and public companies; (B)…

    Published on 5/25/2015
  • Innovation underfed

    Europe's Iceberg 2015: Finance at root of translational gap in innovation

    Innovation is a predictor of access to capital and partnering success, but investors say lack of the former is holding back Europe's innovators.

    Published on 5/25/2015
  • Figure: Capital rationing

    Innovation underfed Capital rationing In 2014, the average venture raised per private European company increased by 21% to $17.5 million from $14.4 million in 2013. The boost was helped by an unspecified $85 …

    Published on 5/25/2015
  • Figure: EU vs. U.S. private funds raised

    Innovation underfed EU vs. U.S. private funds raised Money raised by private U.S. companies increased by 61% to $6.5 billion in 2014 from 2013, while European private companies saw a 11% increase in funding to $1.…

    Published on 5/25/2015
  • Figure: EU vs. U.S. public funds raised

    Innovation underfed EU vs. U.S. public funds raised The top figure shows that the amount raised via equity financings by public European biotechs increased by 2.6x to $4.7 billion from 2013 vs. a 1.5x increase in …

    Published on 5/25/2015
  • Figure: Global competition for capital

    Innovation underfed Global competition for capital Total funding for both Europe and the U.S. increased from 2013 to 2014. The money raised by European companies increased by 57% to $9 billion, while U.S. …

    Published on 5/25/2015
  • Figure: Innovation pays

    Innovation underfed Innovation pays Of 225 private Phase II companies included in BioCentury's annual European Iceberg survey from 2011 to 2013, a subset of 133 deemed innovators raised significantly more cash, …

    Published on 5/25/2015
  • Cash cravings

    Results of BioCentury's 13th survey of funding needs for European biotechs

    BioCentury's 13th annual European Iceberg survey foresees record financing demand, lifted by higher cash burn and more public biotechs.

    Published on 5/25/2015
  • Table: Shrugging off IPRs

    Cut bait Shrugging off IPRs Activists and investors, including but not limited to Kyle Bass, have filed petitions with the U.S. Patent and Trademark Office for inter partes reviews (IPRs) of patents covering at …

    Published on 5/18/2015
  • Reforming IPR

    How BIO, PhRMA aim to get IPR reform into Senate's patent bill

    Influential senators are sympathetic to drug company complaints about the IPR process, but the House is less receptive to reforms.

    Published on 5/18/2015
  • Cut bait

    Why Congress may reform the inter partes review process on patents

    The threat from Kyle Bass' use of inter partes review has been exaggerated, but the publicity could lead to reforms.

    Published on 5/18/2015
  • Table: State of transparency

    Transparency scorecard State of transparency Lawmakers in five states have introduced transparency bills that would require companies to disclose R&D and SG&A expenses for certain drugs, along with those products'…

    Published on 5/11/2015
  • Transparency scorecard

    Why Mass. price transparency bill could succeed where others have failed

    Three drug price transparency bills have died on the vine, but the Massachusetts bill could pose the biggest challenge to the industry.

    Published on 5/11/2015
  • Shorter and fatter

    How 21st Century Cures draft boosts NIH budget, addresses FDA concerns

    New 21st Century Cures discussion draft gives NIH more money, reduces burden on FDA and eliminates proposed new drug exclusivities.

    Published on 5/4/2015
  • Box: An innovative fund

    Shorter and fatter An innovative fund The 21st Century Cures discussion draft released last week sidesteps standard congressional appropriations procedures to allocate $2 billion per year for five years to an NIH…

    Published on 5/4/2015
  • Speed trials

    How the Ebola outbreak sparked the fastest vaccine development efforts ever

    Collaborations to combat Ebola are developing vaccines at record speeds and could be creating a new model for responding to crises.

    Published on 4/27/2015
  • Figure: Record time

    Speed trials Record time Ad hoc collaborations among multinational pharma companies, government funding and research agencies, NGOs and philanthropic foundations have dramatically accelerated Ebola vaccine …

    Published on 4/27/2015
  • Learning from Ebola

    What lessons from Ebola can prepare society for other outbreaks

    The Ebola crisis should be an inflection point in global health and emerging infectious disease R&D.

    Published on 4/27/2015
  • Box: Getting pCR right

    FDA's rocket docket Getting pCR right Three years after publishing draft guidance on the use of pathologic complete response (pCR) as a surrogate endpoint for accelerated approval of neoadjuvant therapy for high-…

    Published on 4/20/2015
  • Box: Moving up in blood cancers

    FDA's rocket docket Moving up in blood cancers Hematologic cancer drug development has been so successful that FDA views it as a paradigm for the development of therapies for other kinds of cancer, Richard Pazdur,…

    Published on 4/20/2015
  • Box: Opdivo urgency

    FDA's rocket docket Opdivo urgency FDA pulled out all the stops to approve Bristol-Myers Squibb Co.'s Opdivo nivolumab to treat patients with metastatic squamous non-small cell lung cancer who have progressed on …

    Published on 4/20/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993